OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	70.33	110.76	29.88	11.54
Cash & Short-Term Investments	70.33	110.76	29.88	11.54
Cash Growth	783.67%	270.74%	158.82%	-
Prepaid Expenses	1.2	2.24	3.89	2.08
Total Current Assets	71.53	113	33.77	13.62
Property, Plant & Equipment	1.21	1.8	1.91	2.05
Other Long-Term Assets	0.1	0.11	0.06	0.33
Total Assets	72.84	114.91	35.73	16
Accounts Payable	1.29	2.97	3.42	2.52
Accrued Expenses	4.39	7.03	3.66	2.87
Current Portion of Leases	0.57	0.54	0.21	0.15
Total Current Liabilities	6.25	10.53	7.29	5.54
Long-Term Leases	0.12	0.55	0.47	0.49
Total Liabilities	6.41	11.08	7.75	6.03
Common Stock	0	0	-	0
Additional Paid-In Capital	267.17	258.55	0.21	2.66
Retained Earnings	-200.74	-154.72	-102.05	-57.07
Total Common Equity	66.43	103.83	-101.84	-54.42
Shareholders' Equity	66.43	103.83	27.98	9.97
Total Liabilities & Equity	72.84	114.91	35.73	16
Total Debt	0.69	1.09	0.67	0.64
Net Cash (Debt)	69.64	109.68	29.2	10.91
Net Cash Growth	4693.12%	275.58%	167.76%	-
Net Cash Per Share	5.23	31.82	102.89	-
Filing Date Shares Outstanding	13.55	13.44	13.34	-
Total Common Shares Outstanding	13.55	13.35	13.34	-
Working Capital	65.28	102.47	26.48	8.08
Book Value Per Share	4.90	7.78	-7.63	-
Tangible Book Value	66.43	103.83	-101.84	-54.42
Tangible Book Value Per Share	4.90	7.78	-7.63	-
Machinery	0.99	1.05	1.01	0.85
Leasehold Improvements	1.09	1.09	1.09	1

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q